BioLineRx Ltd.
BLRX
$3.85
$0.112.94%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.19% | 91.68% | 502.92% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.19% | 91.68% | 502.92% | -- | -- |
| Cost of Revenue | 16.10% | 52.36% | 150.89% | -- | -- |
| Gross Profit | -7.00% | 122.77% | 1,675.90% | -- | -- |
| SG&A Expenses | -57.17% | -32.80% | -6.02% | 22.13% | 78.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -41.19% | -22.82% | 0.63% | 26.08% | 51.44% |
| Operating Income | 61.94% | 57.08% | 55.45% | 29.55% | -1.66% |
| Income Before Tax | 74.03% | 93.09% | 84.79% | 62.03% | 30.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 74.03% | 93.09% | 84.79% | 62.03% | 30.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 74.03% | 93.09% | 84.79% | 62.03% | 30.42% |
| EBIT | 61.94% | 57.08% | 55.45% | 29.55% | -1.66% |
| EBITDA | 66.75% | 62.16% | 62.32% | 35.37% | 2.62% |
| EPS Basic | 77.89% | 90.94% | 88.17% | 68.25% | 37.78% |
| Normalized Basic EPS | 76.82% | 92.14% | 88.83% | 79.44% | 50.49% |
| EPS Diluted | 77.89% | 90.94% | 88.17% | 68.25% | 37.78% |
| Normalized Diluted EPS | 76.82% | 92.14% | 88.83% | 79.44% | 50.49% |
| Average Basic Shares Outstanding | 65.32% | 47.44% | 24.35% | 23.32% | 22.23% |
| Average Diluted Shares Outstanding | 65.32% | 47.44% | 24.35% | 23.32% | 22.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |